Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes- Dose-response association with all-cause mortality, cardiovascular events, and incident cancer
Abstract
Authors
S.E. Holden S. Jenkins-Jones C.L. Morgan G. Schernthaner C.J. Currie